Payment overview · 2025
General Payments
$218.20
13 reported records · 6 companies
Healthcare provider profile · identity verified
Avery Lyne Sides, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, SD · NPI 1629360342
Verified facts
What the public records show
CMS Open Payments records show Avery Lyne Sides, M.D. received $218.20 in general payments during 2025 across 13 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $85.22 | 39.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.41 | 22.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.94 | 15.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.46 | 8.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.31 | 7.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.86 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $218.20 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $53.87 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.41 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.41 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $31.35 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 386 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 384 | 85 |
| Losartan Potassium | Losartan Potassium | 341 | 87 |
| Omeprazole | Omeprazole | 243 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 54 |
| Lisinopril | Lisinopril | 225 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 39 |
| Furosemide | Furosemide | 151 | 46 |
| Trazodone Hcl | Trazodone Hcl | 147 | 35 |
| Montelukast Sodium | Montelukast Sodium | 140 | 39 |
| Gabapentin | Gabapentin | 137 | 48 |
| Eliquis | Apixaban | 134 | 31 |
| Potassium Chloride | Potassium Chloride | 125 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 23 |
| Finasteride | Finasteride | 100 | 19 |
| Spironolactone | Spironolactone | 91 | 21 |
| Metformin Hcl Er | Metformin Hcl | 89 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 32 |
| Sertraline Hcl | Sertraline Hcl | 84 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 18 |
| Meloxicam | Meloxicam | 74 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 34 |
| Allopurinol | Allopurinol | 71 | 19 |
| Tramadol Hcl | Tramadol Hcl | 71 | 31 |
| Metformin Hcl | Metformin Hcl | 69 | 21 |
| Estradiol | Estradiol | 68 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 15 |
| Synthroid | Levothyroxine Sodium | 63 | 15 |
| Simvastatin | Simvastatin | 62 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 12 |
| Prednisone | Prednisone | 60 | 52 |
| Famotidine | Famotidine | 59 | 17 |
| Ezetimibe | Ezetimibe | 58 | 14 |
| Cephalexin | Cephalexin | 57 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 15 |
| Irbesartan | Irbesartan | 52 | suppressed |
| Ozempic | Semaglutide | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 13 |
| Jardiance | Empagliflozin | 50 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 11 |
| Bupropion Xl | Bupropion Hcl | 44 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Pregabalin | Pregabalin | 40 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 39 | suppressed |
| Baclofen | Baclofen | 38 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | 11 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | 13 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Carvedilol | Carvedilol | 33 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 12 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Dulera | Mometasone/Formoterol | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 28 | 12 |
| Alprazolam | Alprazolam | 27 | 11 |
| Lidocaine | Lidocaine | 27 | suppressed |
| Premarin | Estrogens, Conjugated | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 22 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 20 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Azithromycin | Azithromycin | 18 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Glimepiride | Glimepiride | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $218.20 · 13 records | E.R. Squibb & Sons, L.L.C. | CAMZYOS, ELIQUIS, EVENITY, LEQVIO, MOUNJARO, Ozempic, PROLIA, Rybelsus, TRELEGY ELLIPTA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error